71 recruiting. 71 Phase 2, 9 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 71 | Recruiting 71 |
| Phase 1 | 9 | Recruiting 9 |
| Phase 3 | 4 | Recruiting 4 |
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS - Treatment Resistant Depression, Treatment Resistant Depression (TRD) | Phase 2 / Phase 3 | Recruiting | NeuroRx, Inc. | 240 | 2026-12-01 | 2026-10-21 |
| A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety CYB003, Placebo - Depression, Anxiety | Phase 2 | Recruiting | Ohio State University | 40 | 2026-11-01 | 2026-10-20 |
| Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression Ketamine (0.5 mg/kg), Behavioural Activation Therapy - Treatment Resistant Depression, Major Depressive Disorder (MDD) | Phase 2 / Phase 3 | Recruiting | The Royal's Institute of Mental Health Research | 60 | 2026-10-30 | 2026-11-09 |
| Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression Sertraline - Major Depressive Disorder (MDD), Probiotic Intervention | Phase 2 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 120 | 2026-10-01 | 2026-06-12 |
| A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder ALKS 7290 Dose, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Alkermes, Inc. | 180 | 2026-10-01 | 2026-10-28 |
| Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder Sham iTBS, TMS, D-cycloserine - Major Depression, Healthy Participants | Phase 1 / Phase 2 | Recruiting | Mclean Hospital | 100 | 2026-10-01 | 2026-10-30 |
| Precision Depression Adalimumab Trial Adalimumab Biosimilars Injection, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Daniel Moriarity | 60 | 2026-09-01 | 2026-09-29 |
| Dupilumab in Major Depressive Disorder Dupilumab Injection - Major Depressive Disorder | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 34 | 2026-08-27 | 2026-11-02 |
| Inhaled DMT for Major Depressive Disorder N,N-Dimethyltryptamine (15 mg + 60 mg), N,N-Dimethyltryptamine (1 mg + 4 mg) - MDD, Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Universidade Federal do Rio Grande do Norte | 140 | 2026-08-01 | 2026-07-13 |
| Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) Ketamine Hydrochloride, Midazolam Hydrochloride, Dialectical Behavioral Therapy (DBT) - Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder | Phase 2 | Recruiting | Joshua Rosenblat | 120 | 2026-07-16 | 2026-07-29 |
| Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression Psilocybin - Treatment-Resistant Depression | Phase 2 | Recruiting | Centre for Addiction and Mental Health | 40 | 2026-07-03 | 2026-08-21 |
| Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ) Psilocybin 25 mg per os, Trazodone 5mg, Trazodone 30 mg - Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD) | Phase 2 | Recruiting | Centre Hospitalier St Anne | 112 | 2026-06-30 | 2026-09-21 |
| A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) TNX-102 SL, Placebo sublingual tablet - Major Depressive Episode (MDE), Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Tonix Pharmaceuticals, Inc. | 360 | 2026-06-25 | 2026-10-30 |
| Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression Sertraline combined with Lactobacillus crispatus, Sertraline combined with placebo - Major Depressive Disorder (MDD), Probiotic Intervention | Phase 2 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 60 | 2026-06-11 | 2026-06-15 |
| Cannabidiol Oil for Treatment-Resistant Major Depression Full-spectrum CBD oil 100 mg/mL, Placebo oil (MCT oil) - Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD) | Phase 1 / Phase 2 | Recruiting | Universidade do Sul de Santa Catarina | 120 | 2026-06-01 | 2026-07-10 |
| ALTO-207 in Adults With Treatment-resistant Depression (TRD) ALTO-207, Placebo - Treatment-resistant Depression (TRD) | Phase 2 | Recruiting | Alto Neuroscience | 178 | 2026-05-20 | 2026-10-26 |
| A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression DT-101, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Draig Therapeutics Ltd | 118 | 2026-05-14 | 2026-10-14 |
| Mindfulness Engaged Neurostimulation for Depression (MEND II) Medi-TBS - Depression, Treatment Resistant Depression | Phase 2 | Recruiting | University of California, San Diego | 120 | 2026-05-01 | 2026-05-06 |
| Neutralizing Interleukin (IL)-6 Tocilizumab - Major Depressive Disorder | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 60 | 2026-03-26 | 2026-04-29 |
| Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder Psilocybin 25 mg, Placebo - Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD) | Phase 2 | Recruiting | Centre for Addiction and Mental Health | 30 | 2026-03-23 | 2026-10-26 |
Showing 20 of 71. Sign in to see all of them.
Depressive Disorder, Major (58) · Depression (23) · Depressive Disorder, Treatment-Resistant (18) · Anxiety Disorders (5) · Inflammation (4) · Mood Disorders (4) · Suicidal Ideation (4) · Suicide (4) · Alcoholism (2) · Bipolar Disorder (2) · Mental Disorders (2) · Schizophrenia (2) · Amyotrophic Lateral Sclerosis (1) · Anhedonia (1)
Mental Disorders (69) · Mood Disorders (67) · Behavior (27) · Behavioral Symptoms (26) · Pathological Conditions, Signs and Symptoms (7) · Self-Injurious Behavior (6) · Pathologic Processes (5) · Nervous System Diseases (4) · Alcohol-Related Disorders (2) · Bipolar and Related Disorders (2) · Central Nervous System Diseases (2) · Chemically-Induced Disorders (2) · Lung Diseases (2) · Neurodegenerative Diseases (2)
Psilocybin (12) · Ketamine (10) · Fluoxetine (2) · Sertraline (2) · Transcranial Magnetic Stimulation (2) · 1-((3-(methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one (1) · 3-(3-(methylsulfonyl)phenyl)-1-propylpiperidine (1) · 5-Hydroxytryptophan (1) · 6-hydroxynorketamine (1) · Cognitive Behavioral Therapy (1) · Counseling (1) · Creatine (1) · Cycloserine (1) · Glucose (1) · Glycyrrhetinic Acid (1)
Centre for Addiction and Mental Health (4) · Icahn School of Medicine at Mount Sinai (4) · National Institute of Mental Health (NIMH) (3) · Alto Neuroscience (2) · China Medical University Hospital (2) · Draig Therapeutics Ltd (2) · Emory University (2) · First Affiliated Hospital of Chongqing Medical University (2) · Massachusetts General Hospital (2) · Mclean Hospital (2) · Syndeio Biosciences, Inc (2) · The Royal's Institute of Mental Health Research (2) · Yale University (2) · ACADIA Pharmaceuticals Inc. (1) · AbbVie (1)
United States (42) · Canada (10) · Brazil (3) · China (3) · Czechia (3) · Germany (3) · United Kingdom (3) · Bulgaria (2) · Denmark (2) · Israel (2) · Poland (2) · Taiwan (2) · Belgium (1) · France (1) · Hungary (1)
Ishrat Husain, MBBS, MD (3) · Carlos A Zarate, M.D. (2) · James Murrough (2) · Jennifer Phillips, PhD (2) · Aaron Koenig, MD (1) · Adam Savitz, MD, PhD (1) · Alan K Davis, PhD (1) · Andreas J Fallgatter, Prof. Dr. (1) · Balwinder Singh, M.D., M.S. (1) · Bradley J MacIntosh, PhD (1) · Daniel P. Moriarity, PhD (1) · Daniel S Pine, M.D. (1)
PMID 42171126, PMID 20717121, PMID 25344944, PMID 26544668, PMID 27210031, PMID 27909164, PMID 28407726, PMID 29625429, PMID 29792726, PMID 30336704, PMID 30616705, PMID 30968800, PMID 31060042, PMID 31064595, PMID 31352029, PMID 31636488, PMID 31656217, PMID 31955915, PMID 32077442, PMID 32138938, PMID 32452462, PMID 32757505, PMID 32954946, PMID 33146667, PMID 33386133, PMID 33440203, PMID 33479511, PMID 35763351, PMID 35794298, PMID 36322843, PMID 36325887, PMID 36442665, PMID 36563874, PMID 36977629, PMID 37651119, PMID 37997749, PMID 38052059, PMID 38355141, PMID 38874947, PMID 38956594, PMID 41555748, PMID 42808010
2019 (1), 2023 (1), 2025 (1), 5KL2TR002379 (1), 5KL2TR002379-08 (1), P50MH119467 (1), R00AA024142 (1), R01MH131194 (1), R01MH132059 (1), R01MH133842 (1), R01MH140180 (1), R01NS125482 (1), R61MH133770 (1)